• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Phase I study of a biweekly schedule of a fixed dose of cisplatin with increasing doses of paclitaxel in patients with advanced oesophageal cancer.晚期食管癌患者中顺铂固定剂量与递增剂量紫杉醇每两周一次给药方案的I期研究。
Br J Cancer. 1999 Jun;80(7):1052-7. doi: 10.1038/sj.bjc.6690462.
2
A phase I dose finding study of a biweekly schedule of a fixed dose of cisplatin with increasing doses of paclitaxel in patients with advanced esophageal cancer.
Semin Oncol. 1997 Dec;24(6 Suppl 19):S19-82-S19-85.
3
A phase I trial of intravenous melphalan, paclitaxel, and cisplatin plus granulocyte-colony stimulating factor in patients with suboptimal advanced epithelial ovarian carcinoma or peritoneal carcinoma.一项关于静脉注射美法仑、紫杉醇和顺铂加粒细胞集落刺激因子用于晚期上皮性卵巢癌或腹膜癌患者的I期试验,这些患者病情欠佳。
Cancer. 1999 Dec 1;86(11):2291-300.
4
Phase I study of dose-escalated paclitaxel, ifosfamide, and cisplatin (PIC) combination chemotherapy in advanced solid tumours.多西他赛、异环磷酰胺和顺铂(PIC)剂量递增联合化疗用于晚期实体瘤的I期研究。
Br J Cancer. 2000 Jan;82(2):300-7. doi: 10.1054/bjoc.1999.0919.
5
A phase I study of paclitaxel, etoposide, and cisplatin in extensive stage small cell lung cancer.一项关于紫杉醇、依托泊苷和顺铂用于广泛期小细胞肺癌的I期研究。
Clin Cancer Res. 1999 Nov;5(11):3419-24.
6
Phase I trial of combined-modality therapy for localized esophageal cancer: escalating doses of continuous-infusion paclitaxel with cisplatin and concurrent radiation therapy.局部食管癌联合治疗的I期试验:顺铂联合持续输注紫杉醇递增剂量及同步放疗。
J Clin Oncol. 2004 Jan 1;22(1):45-52. doi: 10.1200/JCO.2004.05.039.
7
Phase II trial of low-dose paclitaxel and cisplatin in patients with advanced gastric cancer.低剂量紫杉醇和顺铂用于晚期胃癌患者的II期试验。
Jpn J Clin Oncol. 2005 Dec;35(12):720-6. doi: 10.1093/jjco/hyi198. Epub 2005 Dec 6.
8
[Phase II study of paclitaxel and cisplatin for advanced squamous-cell carcinoma of esophagus].紫杉醇和顺铂治疗晚期食管鳞状细胞癌的II期研究
Zhonghua Zhong Liu Za Zhi. 2004 Dec;26(12):753-5.
9
A dose-finding study of raltitrexed (tomudex) with cisplatin and epirubicin in advanced gastro-oesophageal adenocarcinoma.雷替曲塞(拓优得)联合顺铂和表柔比星用于晚期胃食管腺癌的剂量探索性研究。
Br J Cancer. 2000 Jun;82(12):1925-31. doi: 10.1054/bjoc.2000.1165.
10
Aggressive simultaneous radiochemotherapy with cisplatin and paclitaxel in combination with accelerated hyperfractionated radiotherapy in locally advanced head and neck tumors. Results of a phase I-II trial.顺铂和紫杉醇同步进行的积极放化疗联合加速超分割放疗用于局部晚期头颈部肿瘤。一项I-II期试验的结果
Strahlenther Onkol. 2003 Oct;179(10):673-81. doi: 10.1007/s00066-003-1106-0.

引用本文的文献

1
Phase I-II study of biweekly paclitaxel administration with fixed-dose-rate cisplatin in advanced gastric cancer.晚期胃癌每两周一次紫杉醇联合固定剂量率顺铂给药的I-II期研究。
Gastric Cancer. 2006;9(1):36-43. doi: 10.1007/s10120-005-0355-2.
2
Bi-weekly chemotherapy of paclitaxel and cisplatin in patients with metastatic or recurrent esophageal cancer.转移性或复发性食管癌患者接受紫杉醇和顺铂的双周化疗。
J Korean Med Sci. 2005 Aug;20(4):618-23. doi: 10.3346/jkms.2005.20.4.618.
3
Gemcitabine and cisplatin for patients with metastatic or recurrent esophageal carcinoma: a Southwest Oncology Group Study.吉西他滨和顺铂用于转移性或复发性食管癌患者:一项西南肿瘤协作组研究
Invest New Drugs. 2004 Jan;22(1):91-7. doi: 10.1023/b:drug.0000006179.20974.af.
4
Prognostic factors for survival in patients with advanced oesophageal cancer treated with cisplatin-based combination chemotherapy.以顺铂为基础的联合化疗治疗晚期食管癌患者生存的预后因素
Br J Cancer. 2003 Dec 1;89(11):2045-50. doi: 10.1038/sj.bjc.6601364.
5
Guidelines for the management of oesophageal and gastric cancer.食管癌和胃癌管理指南。
Gut. 2002 Jun;50 Suppl 5(Suppl 5):v1-23. doi: 10.1136/gut.50.90005.v1.
6
New developments in the treatment of esophageal cancer.食管癌治疗的新进展。
Curr Oncol Rep. 2002 May;4(3):213-21. doi: 10.1007/s11912-002-0018-y.
7
Phase II study of bi-weekly administration of paclitaxel and cisplatin in patients with advanced oesophageal cancer.紫杉醇和顺铂每两周给药一次用于晚期食管癌患者的II期研究。
Br J Cancer. 2002 Mar 4;86(5):669-73. doi: 10.1038/sj.bjc.6600166.

本文引用的文献

1
Chemotherapy in oesophageal cancer.
Cancer Treat Rev. 1997 Mar;23(2):65-85. doi: 10.1016/s0305-7372(97)90021-9.
2
Phase I dose escalation of paclitaxel in patients with advanced ovarian cancer receiving cisplatin: rapid development of neurotoxicity is dose-limiting.接受顺铂治疗的晚期卵巢癌患者中紫杉醇的Ⅰ期剂量递增研究:神经毒性的快速出现是剂量限制性因素。
J Clin Oncol. 1997 May;15(5):1965-73. doi: 10.1200/JCO.1997.15.5.1965.
3
Phase II trial of biweekly paclitaxel and cisplatin in advanced breast carcinoma: an Eastern Cooperative Oncology Group study.
J Clin Oncol. 1997 May;15(5):1880-4. doi: 10.1200/JCO.1997.15.5.1880.
4
A phase I study of bi-weekly paclitaxel/cisplatin as initial therapy for advanced ovarian cancer. A study of the National Cancer Institute of Canada Clinical Trials Group.
Ann Oncol. 1996 Dec;7(10):1077-9. doi: 10.1093/oxfordjournals.annonc.a010502.
5
Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer.紫杉醇每周给药用于复发性卵巢癌患者的I期和药理学研究。
J Clin Oncol. 1997 Jan;15(1):187-92. doi: 10.1200/JCO.1997.15.1.187.
6
Paclitaxel in the treatment of patients with upper gastrointestinal carcinomas.紫杉醇用于治疗上消化道癌患者。
Semin Oncol. 1996 Oct;23(5 Suppl 12):55-8.
7
National Cancer Data Base report on esophageal carcinoma.国家癌症数据库关于食管癌的报告。
Cancer. 1996 Oct 15;78(8):1820-8. doi: 10.1002/(sici)1097-0142(19961015)78:8<1820::aid-cncr25>3.0.co;2-z.
8
Cisplatin and etoposide in oesophageal cancer: a phase II study. Rotterdam Oesophageal Tumour Study Group.顺铂和依托泊苷用于食管癌治疗:一项II期研究。鹿特丹食管癌研究组
Br J Cancer. 1996 Sep;74(6):980-4. doi: 10.1038/bjc.1996.469.
9
Paclitaxel delivered as a 3-hr infusion with cisplatin in patients with gynecologic cancers: unexpected incidence of neurotoxicity.在妇科癌症患者中,紫杉醇与顺铂联合进行3小时输注:神经毒性的意外发生率。
Gynecol Oncol. 1996 Aug;62(2):166-8. doi: 10.1006/gyno.1996.0210.
10
Phase I/II trial of biweekly paclitaxel and cisplatin in the treatment of metastatic breast cancer.每两周一次紫杉醇和顺铂治疗转移性乳腺癌的I/II期试验
J Clin Oncol. 1996 Apr;14(4):1185-91. doi: 10.1200/JCO.1996.14.4.1185.

晚期食管癌患者中顺铂固定剂量与递增剂量紫杉醇每两周一次给药方案的I期研究。

Phase I study of a biweekly schedule of a fixed dose of cisplatin with increasing doses of paclitaxel in patients with advanced oesophageal cancer.

作者信息

van der Gaast A, Kok T C, Kerkhofs L, Siersema P D, Tilanus H W, Splinter T A

机构信息

Department of Medical Oncology, University Hospital Rotterdam-Dijkzigt, Rotterdam, The Netherlands.

出版信息

Br J Cancer. 1999 Jun;80(7):1052-7. doi: 10.1038/sj.bjc.6690462.

DOI:10.1038/sj.bjc.6690462
PMID:10362115
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2363040/
Abstract

We performed this dose-finding study with a fixed dose of cisplatin and increasing doses of paclitaxel given every 2 weeks to determine the maximum tolerable dose of this schedule. Sixty-four patients with advanced oesophageal cancer were treated with a cisplatin dose of 60 mg m(-2) and increasing doses of paclitaxel from 100 mg m(-2) up to 200 mg m(-2) both administered over 3 h for a maximum of six cycles in patients with stable disease or eight cycles in responding patients. Patients were retreated when the granulocytes were > 0.75 x 10(9) l(-1) and the platelets > 75 x 10(9) l(-1). The dose of paclitaxel could be increased to 200 mg m(-2) without encountering dose limiting haematological toxicity. At the dose levels 190 mg m(-2) and 200 mg m(-2) of paclitaxel cumulative sensory neurotoxicity became the dose-limiting toxicity. The dose intensity of paclitaxel calculated over six cycles rose from 50 mg m(-2) per week to 85 mg m(-2) per week. Only three episodes of granulocytopenic fever were encountered out of a total of 362 cycles of treatment. Of the 59 patients evaluable for response, 31 (52%) had a partial or complete response. In a biweekly schedule with a fixed dose of 60 mg m(-2) cisplatin it is possible to increase the dose of paclitaxel to 180 mg m(-2). At higher dose levels, neurotoxicity becomes the dose-limiting toxicity. The observed response rate warrants further investigation of this schedule.

摘要

我们进行了这项剂量探索研究,每2周给予固定剂量的顺铂和递增剂量的紫杉醇,以确定该方案的最大耐受剂量。64例晚期食管癌患者接受了60mg/m²的顺铂剂量,并给予递增剂量的紫杉醇,从100mg/m²至200mg/m²,两种药物均在3小时内给药,病情稳定的患者最多接受6个周期治疗,有反应的患者最多接受8个周期治疗。当粒细胞计数>0.75×10⁹/L且血小板计数>75×10⁹/L时,患者可再次接受治疗。紫杉醇剂量可增至200mg/m²,而未出现剂量限制性血液学毒性。在紫杉醇剂量为190mg/m²和200mg/m²时,累积感觉神经毒性成为剂量限制性毒性。计算得出的六个周期内紫杉醇的剂量强度从每周50mg/m²升至每周85mg/m²。在总共362个治疗周期中,仅出现3次粒细胞减少性发热。在59例可评估反应的患者中,31例(52%)有部分或完全反应。在每2周一次的方案中,给予固定剂量60mg/m²的顺铂时,可将紫杉醇剂量增至180mg/m²。在更高剂量水平时,神经毒性成为剂量限制性毒性。观察到的反应率值得对该方案进行进一步研究。